Endometrial hyperplasia is a very frequent pathology during menopause and involves the risk of the malignant transformation of lesions and the onset of anemia due to concomitant clinical phenomena. Standard medical treatments often involve major collateral effects which impede their long-term use. In an attempt to avoid radical surgery for many women or the use of other invasive techniques, this paper proposes the use of Leuprolide acetate which was used to treat 30 patients with histologically confirmed symptoms of endometrial hyperplasia without atypia. This controlled-session LHRH analog was administered using an intramuscular route every 30 days for 6 months. Hysteroscopic and histological controls were carried out 30 days after the last treatment and showed the resolution of histological and clinical symptoms; this was confirmed after 3 months. Fibroma, which are the most frequently associated pathology, were considerably reduced.